Keyword Analysis & Research: acumen pharmaceuticals

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
acumen pharmaceuticals1.330.545227922
acumen1.2311253576
pharmaceuticals1.850.986906215

Keyword Research: People who searched acumen pharmaceuticals also searched

Keyword CPC PCC Volume Score
acumen pharmaceuticals1.080.7335618

Search Results related to acumen pharmaceuticals on Search Engine

  • Home | Acumen Pharmaceuticals

    acumenpharm.com

    https://acumenpharm.com/

    WEBAcumen means keenness and depth of perception. That’s exactly who we are: an experienced, tenacious team singularly focused on developing targeted therapies for Alzheimer’s disease, building upon current momentum to drive the field forward and achieve even better outcomes.

    DA: 26 PA: 28 MOZ Rank: 67

  • News Releases | Acumen Pharmaceuticals, Inc

    acumenpharm.com

    https://investors.acumenpharm.com/news-events/news-releases

    WEBApr 16, 2024 · CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management.

    DA: 43 PA: 45 MOZ Rank: 75

  • About Us | Acumen Pharmaceuticals

    acumenpharm.com

    https://acumenpharm.com/about-us/

    WEBAbout Us. At Acumen, we are singularly focused on the development of targeted therapies for Alzheimer’s disease, a condition that has remained untreatable for far too long. We are at a breakthrough moment for Alzheimer’s disease research and drug development.

    DA: 84 PA: 75 MOZ Rank: 95

  • Investor Relations | Acumen Pharmaceuticals, Inc

    acumenpharm.com

    https://investors.acumenpharm.com/

    WEBThe Investor Relations website contains information about Acumen Pharmaceuticals, Inc's business for stockholders, potential investors, and financial analysts.

    DA: 33 PA: 62 MOZ Rank: 83

  • Acumen Pharmaceuticals, Inc. (ABOS) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/ABOS/

    WEBAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted...

    DA: 31 PA: 98 MOZ Rank: 62

  • Acumen Pharmaceuticals Presents Late-Breaker Phase 1 …

    acumenpharm.com

    https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-late-breaker-phase-1-updates

    WEBOct 27, 2023 · CHARLOTTESVILLE, Va. and INDIANAPOLIS, Ind., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today …

    DA: 53 PA: 47 MOZ Rank: 86

  • Acumen Pharmaceuticals Presents Positive Topline Results from …

    acumenpharm.com

    https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-positive-topline-results-first

    WEBJul 16, 2023 · CHARLOTTESVILLE, Va. and CARMEL, Ind., July 16, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today presented …

    DA: 37 PA: 96 MOZ Rank: 17

  • Our Science | Acumen Pharmaceuticals

    acumenpharm.com

    https://acumenpharm.com/science/

    WEBAcumen’s therapeutic target for Alzheimer’s disease is different from historical approaches. Decades of research support the hypothesis that soluble AβOs are the most toxic form of Aβ. AβOs are an early trigger and persistent driver of Alzheimer’s-associated pathology and neurodegeneration. 1,2,4

    DA: 82 PA: 83 MOZ Rank: 11

  • Acumen Pharmaceuticals, Inc. | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/acumen-pharm

    WEBinvestors.acumenpharm.com. 63. Acumen Pharmaceuticals, Inc. | 3,820 followers on LinkedIn. Forging a new path towards a safe and effective treatment for Alzheimer’s disease. | Acumen is forging ...

    DA: 68 PA: 98 MOZ Rank: 24

  • Acumen Pharmaceuticals Reports Third Quarter 2023 Financial …

    acumenpharm.com

    https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-third-quarter-2023-financial

    WEBCHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today …

    DA: 4 PA: 29 MOZ Rank: 25